Zanubrutinib CAS# 1691249-45-2 扎努布鲁替尼

Zanubrutinib (BGB-3111) is a potent, selective, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with demonstrated efficacy both in vitro and in vivo. In vitro, it effectively inhibits BTK activity with an IC₅₀ of approximately 0.35 nM, showing high selectivity over other kinases such as EGFR and ITK, and minimal off-target effects on kinases like JAK3. In vivo, zanubrutinib has shown significant therapeutic potential in animal models of hematological malignancies, including mantle cell lymphoma, where it effectively suppressed tumor growth and improved survival rates. Additionally, it has demonstrated efficacy in models of pulmonary fibrosis and cardiac fibrosis, attenuating disease progression through mechanisms involving inhibition of TGF-β1/Smad and TGF-β1/mTOR signaling pathways.